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a  b  s  t  r  a  c  t
The  classical  view  that  only  adaptive  immunity  can  build  immunological  memory  has  recently  been
challenged.  Both  in organisms  lacking  adaptive  immunity  as  well  as  in  mammals,  the  innate  immune
system  can  adapt  to  mount  an  increased  resistance  to reinfection,  a de  facto innate  immune  memory
termed  trained  immunity.  Recent  studies  have  revealed  that  rewiring  of  cellular  metabolism  induced
by  different  immunological  signals  is a  crucial  step  for determining  the epigenetic  changes  underlying
trained  immunity.  Processes  such  as  a shift  of glucose  metabolism  from  oxidative  phosphorylation  to
aerobic  glycolysis,  increased  glutamine  metabolism  and  cholesterol  synthesis,  play  a crucial  role  in  these
processes.  The  discovery  of  trained  immunity  opens  the  door  for the  design  of  novel generations  of
vaccines,  for  new  therapeutic  strategies  for the treatment  of  immune  deﬁciency  states,  and  for  modulation
of exaggerated  inﬂammation  in  autoinﬂammatory  diseases.
© 2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Classically, the immune system can be divided into innate and
adaptive immunity, with monocytes, macrophages, neutrophils,
and NK cells as the main cellular effectors of innate immune
responses, while T- and B-lymphocytes mediate adaptive immu-
nity. Until recently it was  assumed only the adaptive immune
system possesses the capacity to mount a memory response and
therefore improve the immunological reaction to a second infec-
tion. However, an increasing amount of evidence accumulates,
suggesting that also the innate immune system possesses adap-
tive characteristics. In plants and non-vertebrates, both lacking an
http://dx.doi.org/10.1016/j.smim.2016.09.002
1044-5323/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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adaptive immune system, it has already been know for several
decades that a memory response could be build that would pro-
tect from a secondary infection [1,2]. Interestingly, this improved
secondary response is not always strictly speciﬁc, as infection with
one pathogen can sometimes also protect from infections with
non-related pathogens [3]. This process has been shown to be epi-
genetically regulated [4]. In retrospect, this (non-speciﬁc) memory,
mediated by the innate immune system, was also seen in mice
strains with known deﬁciencies in adaptive immune responses
[3,5].
More recently, this same process of innate immune mem-
ory was also been shown to occur in human monocytes and
macrophages. -glucan, a major component of the C. albicans
cell wall, was shown to ex vivo enhance cytokine production to
a second unrelated stimulus, a process that was also epigenet-
ically regulated [6,7]. Also in mice, an in vivo challenge with
-glucan protected from subsequent C. albicans or S. aureus infec-
tion [6,8], and infection with cytomegalovirus induced improved
effector function of NK cells after the infection [9]. In humans,
vaccination with Bacillus Calmette-Guérin (BCG) showed non-
speciﬁc protection from all-cause mortality, mainly a result of
reduced mortality from infections, in low-weight birth children
in West-Africa [10,11]. In a vaccination study in healthy adult
volunteers, BCG markedly increased ex vivo cytokine responses
by inducing epigenetic reprogramming in myeloid cells [12].
These studies demonstrate that the innate immune system can
adapt after a previous challenge through functional and epige-
netic reprogramming, a process that has been termed trained
immunity or innate immune memory [13,14]. On the one hand,
trained immunity is likely an important host defense mecha-
nism contributing to the maturation of the innate immune system
of infants and mediating protection after certain infections or
vaccinations. On the other hand, when induced inappropriately
by endogenous stimuli, trained immunity may  play a role in
the pathogenesis of autoinﬂammatory and/or autoimmune dis-
eases [14,15]. Therefore, better understanding of the molecular
mechanisms of trained immunity is crucial for developing new
ways of immunotherapy and targeting inﬂammatory disorders
[14].
In the last years an increasing amount of evidence has been
accumulated in support of the concept that cellular metabolism
is correlated with the functional state of immune cells [16]. Some
of the ﬁrst observations reported that different subsets of lympho-
cytes had distinctly different cellular metabolic states. Activated T
lymphocytes have high rates of both glycolysis and oxidative phos-
phorylation (OxPhos) and metabolize glucose to lactate [17,18],
whereas memory T-lymphocytes are more dependent on lipid syn-
thesis via mitochondrial citrate production. These lipids can be
used to produce triacyglycerides (TAGs) which are being degraded
by -oxidation to fuel OxPhos via acetyl-CoA production [19]. In
contrast, regulatory T-cells fuel -oxidation and OxPhos through
exogenously derived fatty acids [20]. This shows that the pheno-
type of lymphocytes highly correlates with the source of energy
that they use [21,22]. Subsequent studies showed that different
phenotypes of macrophages retrieve energy from very distinct
metabolic pathways: the more inﬂammatory (M(IFN) or formerly
M1)  macrophages depend largely on glycolysis and show impaired
OxPhos and disruption of the Tricarboxylic acid (TCA) cycle [23,24],
while in the more anti-inﬂammatory (M(IL-4) or formerly M2)
macrophages the Krebs cycle is intact as they rely on OxPhos [25,26]
and furthermore show increased -oxidation as a result of fatty acid
uptake [27].
In this review we will focus on the metabolic pathways induced
by innate immune training. We  will discuss glycolysis, TCA cycle,
glutamine, and cholesterol metabolism and discuss their (poten-
tial) effect on epigenetics and how these clues could be used as
therapeutic targets.
2. Metabolic pathways in trained immunity
2.1. Glycolysis
A metabolic switch from oxidative phosphorylation to gly-
colysis resulting in more lactate production has been described
in the highly metabolically active cancer cells already in the
beginning of the last century by Otto Warburg, called thus the
‘Warburg effect’ [28]. Glycolysis is often increased during immune
cell activation: activated T cells show increased rates of glycol-
ysis [17,18] and proinﬂammatory macrophages increase glucose
metabolism resulting in increased lactate production [24]. This
switch is assumed to be important as glycolysis, although being less
efﬁcient in generating adenosine triphosphate (ATP), can be upreg-
ulated multiple folds and therefore results in a faster production of
ATP compared to oxidative phosphorylation [28].
A similar switch is seen in -glucan trained monocytes [29]
(Fig. 1). Transcriptional and epigenetic (H3K4me3 and H3K27ac)
analysis of -glucan induced trained immunity in monocytes
revealed that genes in the mTOR signalling pathway and several
metabolic pathways, especially glycolysis, were highly induced
[7,29]. When human monocytes are stimulated in vitro with -
glucan for 24 h and let to rest for 6 subsequent days, the amounts of
glucose consumption and lactate production increased over time. In
contrast, oxygen consumption 6 days after -glucan training is sig-
niﬁcantly decreased compared to control macrophages [29]. These
effects of -glucan-induced training were mediated by activation
of the Akt/mTOR/Hif1 pathway. Inhibiting this pathway at sev-
eral levels, or making use of myeloid cell speciﬁc Hif1 knockout
mice, abrogated induction of trained immunity both at cytokine
and epigenetic level [29] (Fig. 1).
Induction of glycolysis results in higher ratios of NAD+/NADH
ratio, which was  also the case in -glucan trained mono-
cytes/macrophages [29]. In LPS stimulated monocytes the vast
increase in NAD+/NADH ratio has been shown to activate sirtuin 1
and 6, supporting a switch from a proinﬂammatory state with high
rates of glycolysis to a more anti-inﬂammatory state with increased
fatty acid oxidation [30]. Interestingly, in -glucan trained mono-
cytes, sirtuin 1 expression appeared to be decreased and activation
of sirtuin 1 by resveratrol inhibited training [29]. This suggests that
decreased expression of sirtuin 1 might play a role in the signiﬁcant
increase of H3K27ac induced by monocyte training by -glucan.
However, apart from the classical role as histone deacetylases, sir-
tuins were also shown to deacetylate nonhistone structutes, such
as NF-B or Hif1 [31], and this should be taken into consideration
too. Moreover, lactate, the end product of anaerobic glycolysis, is
also able to inhibit histone deacetylase (HDAC) activity and there-
fore cause increased gene accessibility [32].
In addition to its direct role in energy production, induction of
glycolysis might also play a role in posttranslational modiﬁcation
of effector molecules. Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), one of the enzymes in glycolysis can bind the 3′ UTR  of
ifng RNA and therefore decreasing IFN production. In activated
T cells GAPDH is used in glycolysis and therefore more IFN can
be produced. Also decreasing GAPDH expression by RNA inter-
ference increased IFN production [33]. A similar mechanism has
been reported in murine and human monocytes and macrophages
in relation to TNF mRNA induction. GADPH can posttranscription-
ally repress TNF mRNA in monocytes in low glycolysis state, e.g.
immunotolerant monocytes as seen in sepsis [34] (Fig. 2). Whether
reversal of such effects plays a role in trained immunity remains to
be elucidated.
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Fig. 1. Glucose metabolism in trained immunity. Induction of trained immunity by -glucan causes activation of the mTOR pathway, effect mediated through signalling via
the  dectin-1 receptor, which results in an increase of Hif1 activity, a central regulating transcription factor of glycolysis-related genes. This results in an upregulation of
glycolysis. Pyruvate, the end product of glycolysis, can be used to fuel the TCA cycle to produce NADH or FADH2, metabolic components that could be used in the electron
transport chain for oxidative phosphorylation (OxPhos). In -glucan trained monocytes pyruvate is converted into lactate, which although less efﬁcient than OxPhos, results
in  more ATP production, as it can be upregulated to a great extent.
Fig. 2. Overview of the complex metabolic pathways that could play a role in trained immunity. Induction of glycolysis resulting in lactate production is one of the central
hallmarks in trained immunity metabolism. In addition, glutamine metabolism, which fuels the TCA cycle and results in accumulation of certain TCA cycle metabolites, such
as  fumarate, is also important for induction of trained immunity. Aspartate consumption from the medium is also increased in trained monocytes and macrophages, while
the  cholesterol synthesis pathway appears to be an essential metabolic pathway as well, as shown by inhibition of trained immunity by statins. Several metabolites that
accumulate in trained monocytes and macrophages could play a role in the induction of epigenetic modulators, such as succinate and fumarate for antagonizing histone or
DNA  demethylation, and acetyl-CoA as an essential substrate for acetylating processes.
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2.2. Tricarboxylic acid cycle
A crucial pathway of energy metabolism in the cell is repre-
sented by the TCA cycle, leading to oxidation of various substrates,
including pyruvate coming from glycolysis. After induction of
trained immunity by -glucan, trained macrophages display a
decreased basal and maximum oxygen consumption, suggestive
for a decrease in use of OxPhos [29]. However, although OxPhos is
decreased, the TCA cycle is not completely shut down, with con-
centrations of several metabolites in the TCA cycle such as citrate,
succinate and fumarate being increased compared to non-trained
macrophages. Increased citrate concentrations might serve as a
source for fatty acid synthesis, as citrate was shown to inhibit gly-
colysis and TCA cycle metabolism, whereas gluconeogenesis and
lipid and sterol synthesis were induced [35–41]. Citrate can either
be produced from glycolysis via pyruvate, or it can be derived from
other metabolites, such as glutamine, which can be converted into
-ketoglutarate and enter the TCA cycle [35,42]. The latter pathway
is especially important in conditions where the mTORC1 pathway
is active which results in Hif1 induction (e.g. trained immunity)
[43], as Hif1 inhibits pyruvate dehydrogenase (PDH) and therefore
carbon incorporation of glycolysis into the TCA cycle [43,44] (Fig. 2).
When citrate is being used as a source for lipid or sterol synthesis, it
ﬁrst should be transported from the mitochondrion into the cytosol
by the citrate carrier (CIC) where it can be converted into acetyl-CoA
by ATP citrate lyase [45] (Fig. 2). Acetyl-CoA is a acetyl donor for
histone acetylation (a histone mark that facilitates transcription)
[46]. Moreover, it has been shown that acetyl-CoA derived from
both glycolysis and glutamine induces histone acetylation of genes
of glycolytic enzymes, such as hexokinase 2, phosphofructokinase,
and lactate dehydrogenase (LDH) [47], therefore promoting glycol-
ysis. Inhibition of, or mutations in, CIC limit histone acetylation,
showing the importance of citrate in histone acetylation [48].
Succinate and fumarate concentrations are also higher in -
glucan trained monocytes and macrophages and both have been
shown to play an important role in inﬂammation [49]. Accumula-
tion of succinate and fumarate has been shown to have a stabilizing
effect on Hif-1 (by inhibiting Prolyl hydroxylases), and thus lead
to an increase in glycolysis and IL-1 transcription [23,50,51].
Apart from the effect on Hif-1, succinate also signals through
the succinate receptor, which in dendritic cells results in intracel-
lular calcium mobilization and synergism with Toll-like receptor
3 (TLR3) and TLR7 and promote their activity [52,53]. Succinate
also results in succinylation of several proteins, e.g. GAPDH, malate
dehydrogenase, LDH and the glutamate carrier 1. However, how
this posttranslational modiﬁcation affects the activity of these pro-
teins remains to be elucidated [23]. Lastly, succinate and fumarate
can act as an antagonist of histone and DNA demethylases. Lysine
demethylases (KDMs) of the JmjC family need -ketoglutarate as
a cofactor for the demethylation process [54] and succinate and
fumarate are known to serve as antagonizing factors [54,55]. For
fumarate it has also been shown that it can inhibit activity of KDM5
demethylases [12,56].
2-hydroxyglutarate concentrations are also higher in
trained monocytes, and this also has antagonizing effects
on -ketoglutarate-dependent demethylases [57]. Hence, 2-
hydroxyglutarate could also serve as an additional factor in
modulating epigenetic marks induced by -glucan.
3. Future directions to study immunometabolism in
trained immunity
3.1. Glutamine metabolism
The metabolite glutamine has been shown to be an essential
source of succinate and fumarate by glutamine anaplerosis and the
GABA shunt [23], and also for citrate via the reverse TCA cycle route
[35]. It should therefore also be determined whether glutamine
metabolism is an important component of trained immunity as
well (Fig. 2). In addition, other effects of glutamine metabolism
may  inﬂuence cell activation during trained immunity. Firstly, glu-
tamate could be used for ATP production, as well as NADPH by
conversion of cytosolic malate to pyruvate. Therefore, mitochon-
drial malate needs to be transported into the cytosol by the malate
shuttle. In addition, cytosolic pyruvate could also be used to main-
tain the NADH redox balance by conversion to lactate. Secondly,
glutamate could be used to produce acetyl CoA, which acts as a sub-
strate for histone acetyltransferases [58]; notably, H3K27Ac is an
important histone mark accompanying active promoters in trained
monocytes [7]. Thirdly, in a glioblastoma cell line, glutamine has
been shown to contribute to the production of cholesterol and fatty
acids, two pathways that were signiﬁcantly upregulated in trained
monocytes [7]. Glutamine enters the TCA cycle via -ketoglutarate
or succinate and is metabolized to citrate (or goes in the reverse
direction [59]) that can be converted into cytosolic acetyl CoA,
which can be used as a direct fuel for cholesterol and fatty acid
synthesis. Fourthly, glutamine could be used to produce malate,
which can be used for fueling the malate-aspartate shuttle. In this
way the reducing equivalents of mitochondrial NADH can be trans-
ported to the cytoplasm for NADPH production, where it might
serve as a cofactor in the cholesterol synthesis pathway, which
is highly induced in -glucan-induced trained immunity (Fig. 2).
Finally, inhibition of glutamine uptake in breast cancer cell lines has
been strongly correlated with reduction of H3K4me3 of essential
genes, modulated by reduced expression of the methyltransferases
SETD1 and ASH2L [60].
3.2. Aspartate metabolism
When consumption of amino acids from the medium of non-
trained and -glucan-trained human macrophages was compared,
consumption of aspartate was  shown to be highly induced in
trained macrophages. Metabolism of aspartic acid serves several
roles, as it is part of the urea cycle, gluconeogenesis, and the malate-
aspartate shuttle, it is important for inosine formation in purine
metabolism, and is a precursor for several amino acids, including
methionine [61]. Aspartate could therefore contribute in several
ways to the induction of trained immunity. Firstly, aspartate might
act by upregulating the malate-aspartate shuttle, which would
result in a transition of the reducing equivalents of mitochon-
drial NADH to NADPH production in the cytoplasm, where it might
serve as an essential metabolite for upregulated cholesterol syn-
thesis (Fig. 2). Secondly, aspartate might serve as fuel for purine
production, which is upregulated in -glucan-trained cells via the
penthose phosphate pathway (PPP) [62]. Thirdly, aspartate can be
used as a source, via transamination of oxaloacetic acid, which
together with acetyl-CoA forms citrate [35] (Fig. 2). Finally, aspar-
tate might serve for the production of essential amino acids such as
methionine, which also serves, just as other metabolic pathways,
such as folate and choline metabolism, as an essential cofactor for
DNA and histone methyltransferases [63,64].
3.3. Cholesterol synthesis
Analysis of transcriptome data of -glucan trained macrophages
revealed that also the cholesterol synthesis pathway was also
highly induced [7]. How the cholesterol synthesis pathway con-
tributes to the phenotype of trained immunity is still to be
elucidated. However, a plausible hypothesis for this effect is that
cholesterol remodels the cell membrane of trained cells, which
could mediate increased signal transduction upon restimulation,
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for example by disrupting cholesterol and sphingolipid raft forma-
tion [65].
4. Future directions to target disease
Immunometabolism is a ﬁeld that has gained more interest the
last several years, and has been shown to be involved in immune
activation in several diseases such as infections [66,67], autoin-
ﬂammatory disorders and cardiovascular diseases [68]. Moreover,
in post-sepsis immunoparalysis, we have shown that the cellular
metabolism of monocytes had broad defects and that reversing
these defects could at least partially restore the immunological
function of these cells [8,69]. Therefore, modulation of cellular
metabolism has great potential as a therapeutic in immune-
mediated diseases. In autoinﬂammatory diseases, atherosclerosis
or insulin resistance and diabetes in which monocytes and
macrophages are thought to be skewed towards a proinﬂammatory
proﬁle, inhibition of certain metabolic pathways may  represent a
valid approach to target disease activity [14,68,70–73]. Moreover,
the role played by cellular metabolic pathways for the induc-
tion of trained immunity may  also represent a novel therapeutic
approach in immunodeﬁciencies. Induction of metabolic pathways
important for trained immunity should be attempted to restore
immune function during sepsis-induced immunoparalysis. In addi-
tion, these approaches could also be used to improve the immune
responsiveness in vulnerable groups such as elderly and infants that
have decreased immune function and are more prone to infectious
diseases [74,75].
In conclusion, boosting or inhibiting the innate immune system
has several potential beneﬁcial effects in different kinds of medical
settings and modulating cellular metabolism of immune cells is a
promising new approach to reach this goal.
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